MedTrace Logo

DPP-4 Inhibition, Incretins and Islet Function

NCT02089438 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-08-23

No results posted yet for this study

Summary

Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and islet hormones. The study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three different DPP-4 inhibitors and placebo.

Conditions

Interventions

DRUG

Saxagliptin

Saxagliptin (5 mg) is given before breakfast

DRUG

Vildagliptin

Vildagliptin (50mg) is given before breakfast and dinner

DRUG

Sitagliptin

Sitagliptin (100 mg) is given before breakfast

Sponsors & Collaborators

  • Lund University

    lead OTHER

Principal Investigators

  • Bo Ahrén, MD, PhD · Lund University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-06-30
Completion
2017-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02089438 on ClinicalTrials.gov